Top Page
Avadel Pharmaceuticals
(NASDAQ:AVDL)
Avadel Pharmaceuticals (AVDL) vs. SPDR S&P 500 ETF (SPY)
Avadel Pharmaceuticals Business Overview & Revenue Model
Avadel Pharmaceuticals Earnings Call Summary
Avadel Pharmaceuticals Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 248.52M | 169.12M | 27.96M | 0.00 | 0.00 | 22.33M |
| Gross Profit | 234.76M | 153.84M | 27.12M | 0.00 | 0.00 | 16.59M |
| EBITDA | 10.13M | -35.57M | -149.13M | -97.60M | -82.39M | 9.60M |
| Net Income | -278.00K | -48.83M | -160.28M | -137.46M | -77.33M | 7.03M |
Balance Sheet | ||||||
| Total Assets | 199.45M | 164.24M | 164.70M | 132.78M | 247.26M | 311.64M |
| Cash, Cash Equivalents and Short-Term Investments | 91.58M | 73.78M | 105.11M | 96.50M | 157.22M | 221.40M |
| Total Debt | 37.38M | 1.70M | 2.62M | 131.02M | 145.00M | 130.52M |
| Total Liabilities | 101.22M | 90.39M | 76.96M | 153.93M | 169.02M | 149.37M |
| Stockholders Equity | 98.22M | 73.85M | 87.74M | -21.14M | 78.24M | 162.27M |
Cash Flow | ||||||
| Free Cash Flow | 35.41M | -46.91M | -128.51M | -71.02M | -77.34M | -48.83M |
| Operating Cash Flow | 35.60M | -46.91M | -128.51M | -70.30M | -77.31M | -48.73M |
| Investing Cash Flow | 10.19M | 51.78M | -50.09M | 79.70M | 56.93M | -69.72M |
| Financing Cash Flow | 5.19M | 15.97M | 135.34M | 14.54M | 263.00K | 179.68M |
Avadel Pharmaceuticals Technical Analysis
Avadel Pharmaceuticals Risk Analysis
Avadel Pharmaceuticals Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $1.26B | 12.13 | 14.84% | ― | -0.03% | -27.66% | |
69 Neutral | $981.78M | ― | 2.90% | ― | 3.14% | ― | |
64 Neutral | $1.90B | 51.74 | 7.83% | ― | 48.87% | ― | |
57 Neutral | $2.09B | ― | -0.32% | ― | 79.88% | 99.60% | |
53 Neutral | $1.53B | ― | -9.54% | ― | 47.83% | 84.72% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $1.17B | ― | -17.46% | ― | -1.19% | 5.06% |
Avadel Pharmaceuticals Corporate Events
On November 14, 2025, Avadel Pharmaceuticals announced receiving an unsolicited acquisition proposal from H. Lundbeck A/S, offering up to $23.00 per ordinary share, which includes cash and contingent value rights based on future sales milestones. The Avadel Board considers this proposal potentially superior to its existing agreement with Alkermes, which offers up to $20.00 per share. However, Avadel’s Board has not yet determined the Lundbeck proposal as superior and continues to support the Alkermes acquisition while engaging in discussions with Lundbeck.
The most recent analyst rating on (AVDL) stock is a Hold with a $20.00 price target. To see the full list of analyst forecasts on Avadel Pharmaceuticals stock, see the AVDL Stock Forecast page.
Avadel Pharmaceuticals, an Irish biopharmaceutical company, specializes in developing treatments for sleep disorders, with its flagship product LUMRYZ targeting narcolepsy. In its latest earnings report, Avadel Pharmaceuticals highlighted a significant increase in net product revenue, reaching $77.5 million for the third quarter of 2025, up from $50 million in the same period last year. This growth was driven by the successful commercialization of LUMRYZ in the U.S., which has been approved for both adult and pediatric use. The company also reported a net income of $20,000 for the quarter, a notable improvement from a loss of $2.6 million in the previous year. Key financial metrics revealed a gross profit of $81.6 million and operating income of $1.9 million, reflecting the company’s effective cost management and increased sales. Additionally, Avadel announced a strategic transaction agreement with Alkermes, expected to close in early 2026, which will see Avadel become a wholly owned subsidiary of Alkermes. Looking ahead, Avadel Pharmaceuticals remains focused on expanding its product portfolio and advancing its clinical trials, with management optimistic about sustaining its growth trajectory and enhancing shareholder value.
The Transaction Agreement in place for Avadel Pharmaceuticals imposes restrictions that limit the company’s ability to engage with third parties regarding alternative acquisition offers. These provisions may deter potential acquirers from proposing competitive bids, as they could be discouraged by the existing agreement’s terms. Consequently, this could result in a lower acquisition price being offered by potential competitors than might otherwise have been proposed. Such limitations could impact Avadel’s strategic options and shareholder value in the context of acquisition negotiations.
On October 22, 2025, Avadel Pharmaceuticals entered into a transaction agreement with Alkermes, under which Alkermes will acquire Avadel for up to $20.00 per share, valuing the transaction at approximately $2.1 billion. This acquisition, expected to close in the first quarter of 2026, will make Avadel a wholly-owned subsidiary of Alkermes, enhancing Alkermes’ entry into the sleep medicine market and expanding its commercial portfolio with Avadel’s product, LUMRYZ™. The deal is anticipated to be immediately accretive, enhancing Alkermes’ revenue growth and profitability, while leveraging Avadel’s established commercial infrastructure and expertise in rare diseases.
The most recent analyst rating on (AVDL) stock is a Buy with a $16.50 price target. To see the full list of analyst forecasts on Avadel Pharmaceuticals stock, see the AVDL Stock Forecast page.
On October 21, 2025, Avadel CNS Pharmaceuticals, a subsidiary of Avadel Pharmaceuticals, reached a settlement with Jazz Pharmaceuticals to resolve multiple lawsuits. As part of the agreement, Jazz will pay Avadel $90 million and waive royalties on LUMRYZ sales through September 30, 2025. Both companies will dismiss their lawsuits, and Jazz will grant Avadel a worldwide license for patents related to LUMRYZ. Avadel will pay Jazz royalties on LUMRYZ sales for narcolepsy and other indications. This settlement provides Avadel with long-term clarity on its intellectual property and commercial rights, positioning it to advance its sleep medicines portfolio.
The most recent analyst rating on (AVDL) stock is a Buy with a $16.50 price target. To see the full list of analyst forecasts on Avadel Pharmaceuticals stock, see the AVDL Stock Forecast page.
On August 29, 2025, Avadel Pharmaceuticals entered into an exclusive global license agreement with XWPharma Ltd. to develop and commercialize valiloxybate, a GABAB receptor agonist, for sleep disorders such as narcolepsy and idiopathic hypersomnia. This agreement, excluding mainland China, Hong Kong, and Macau, involves a $20 million upfront payment to XWPharma, with potential milestone and royalty payments based on sales achievements. The development of valiloxybate is expected to enhance Avadel’s sleep medicine portfolio and leverage its existing infrastructure for efficient clinical and regulatory advancement.
The most recent analyst rating on (AVDL) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Avadel Pharmaceuticals stock, see the AVDL Stock Forecast page.